Innovimmune

Join us at our poster presentation of our preclinical findings of INV-71 ROR gamma agonists for breast cancer #ESMO22 #breastcancer #immunotherapy linkedin.com/feed/update/ur…

Updated 5-year results of the Unicancer PRODIGE 24/CCTG PA6 trial confirmed the significant improvement in all outcomes, including overall survival, with mFOLFIRINOX regimen compared to gemcitabine in adjuvant setting for pts w #pancreaticcancer. ja.ma/3Qd4dgS #GICSM

@wiengesundheit linkedin.com/feed/update/ur…

➡️ NEUE Zutrittsregelungen in unseren Kliniken. Alle Informationen dazu gibt es hier: gesundheitsverbund.at/besuchsregeln/

We are pleased to announce the presentation of INV-71 ROR gamma modulators in preclinical breast cancer at #ESMO22 Paris by presenting author Prof. Sebesta, Chair, Vienna Cancer Center. bit.ly/3CPxLON @cityofhope @uscnorris @Innovimmune @wiengesundheit @myESMO

Explore our first-in-class, best-in-class oral therapies for Cancer and Autoimmune, Inflammatory & Rare diseases. Let's meet at BIO 2022 in San Diego. lnkd.in/eqdDRRmb #bio2022 #cancer #cancertreatment #autoimmune #raredisease #inflammation

Thanks to all colleagues for the enthusiasm and engaging brainstorming session on our Oral INV-88 MIF inhibitors #AACR22 @AACR @ASCO @myESMO @cityofhope @Innovimmune #KlinikDonaustadt

@bradloncar Exactly, but also by lack of "diversity". It is imperative to focus on targets of the other immune compartments as well BEYOND B, need more Rx approaches against NK, MΦ, T, MDSC. @matthewherper @bradloncar @AGKootenay @PharmaceuticBen @JohnCendpts

The mRNA + CART data at #AACR22 is theoretically a cool idea. Cell Tx field has been held back by a lack of antigens naturally as good as CD19 and BCMA. So let’s try making them.

Natural killer cells, primed with an antibody, induce remissions in patients with advanced lymphoma By @adamfeuerstein #AACR22. statnews.com/2022/04/10/ant…

A critical tumorigenic cytokine Macrophage Migration Inhibitory Factor (MIF), a difficult intractable drug target, now druggable with oral small molecules! Innovimmune presents INV-88 #AACR22 @AACR @cityofhope @FollowStevens #KlinikDonaustadt @wiengesundheit @ESMO @ASCO

@matthewherper @adamfeuerstein @damiangarde Me and my colleagues in the drug development world have been great followers (before Social Media!) of you for 25 years. Congratulations for your outstanding scientific journalism. @Innovimmune

About last week -- I wanted to make a note to the world that it was humbling and gratifying to stand with @adamfeuerstein and @damiangarde Friday as we received the Polk Award for medical reporting. Here's Adam, accepting the award for all of us... 1 of 4

For readers interested in harnessing natural killer cells for cancer immunotherapy, for which promising early-stage results have been reported at #AACR22, here's a comprehensive recent review go.nature.com/3Oe57Kv Readcube version rdcu.be/cK6Hs

Great talk exploring associations between genomics of lung cancer and ethnicity by Matt Meyerson featuring work of @CarrotJian (aacrjournals.org/cancerdiscover…) #AACR22

Wie funktioniert die #Chemotherapie & was passiert bei der Immuntherapie? Christian Sebesta, Vorstand der 2. Med. der #KlinikDonaustadt, erklärt was bei diesen Therapieformen mit dem Körper passiert. Patient Walter Vock gibt Einblick in seinen Behandlungsverlauf.

Innovimmune announces presentation of it’s novel cancer immunotherapy program: Oral INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors, at the 2022 AACR Meeting in New Orleans. Learn more. bit.ly/36VjpP1 #AACR22 #immunotherapy #oncology #cancer @AACR

A few early themes from #AACR22, via @evaluatevantage bit.ly/34riu7M

Meet us during #BIODigital week, June 8-12, for a virtual gathering of the global biotech industry! invt.io/1tdb9u2ep0i

#PartneringAgainstCovid19 We are seeking out-licensing partners for the fast-tracked development of our proprietary INV-88 oral macrophage migration inhibitory factor inhibitors tinyurl.com/y9urv9mx as a novel anti-cytokine-storm targeted therapy for ARDS in COVID-19.

Blocking Macrophage Migration Inhibitory Factor a more elegant approach vs targeting proinflammatory IL-6, IL-1b in ameliorating cytokine release syndrome in COVID-19? tinyurl.com/qwppom4 #MIF #INV-88 #COVID-19